PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.54%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.12B
AUM Growth
-$493M
(-8.8%)
Cap. Flow
-$685M
Cap. Flow
% of AUM
-13.38%
Top 10 Holdings %
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42
Avg Time Held Equity + Options
1.5
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$101M |
| 2 |
Relay Therapeutics
RLAY
|
+$70.2M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$59.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$39.8M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$122M |
| 2 |
Arcellx
ACLX
|
+$95.6M |
| 3 |
Boston Scientific
BSX
|
+$93.3M |
| 4 |
Amicus Therapeutics
FOLD
|
+$90.7M |
| 5 |
Astria Therapeutics
ATXS
|
+$84.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Orchestra BioMed
OBIO
$339M
| $21.4M | 0.42% |
5,037,906
-89,350
| -2% | -$380K |
2023 Q1
12 quarters
|
|
52
Rapport Therapeutics
RAPP
$1.36B
| $21.1M | 0.41% |
673,923
| – | – |
2025 Q3
2 quarters
|
|
53
DBV Technologies S.A. American Depositary Shares
DBVT
$557M
| $20.1M | 0.39% |
+964,391
| New | +$20.1M |
2026 Q1
0 quarters
|
|
54
LeonaBio Inc
LONA
$50.8M
| $19.1M | 0.37% |
1,859,322
| – | – |
2020 Q3
22 quarters
|
|
55
Anteris Technologies
AVR
$610M
| $19M | 0.37% |
3,425,476
+1,750,000
| +104% | +$10.1M |
2024 Q4
5 quarters
|
|
56
Sutro Biopharma
STRO
$174M
| $17.8M | 0.35% |
+715,307
| New | +$12.9M |
2026 Q1
0 quarters
|
|
57
Tango Therapeutics
TNGX
$3.74B
| $16.9M | 0.33% |
808,153
+295,118
| +58% | +$4.11M |
2025 Q4
1 quarter
|
|
58
Contineum Therapeutics
CTNM
$306M
| $16.4M | 0.32% |
1,255,592
-209,000
| -14% | -$2.8M |
2024 Q2
7 quarters
|
|
59
Palisade Bio
PALI
$258M
| $15.6M | 0.31% |
8,928,149
-3,121,851
| -26% | -$5.68M |
2025 Q4
1 quarter
|
|
60
Oculis Holding
OCS
$442M
| $13.1M | 0.26% |
493,827
| – | – |
2025 Q4
1 quarter
|
|
61
iRhythm Holdings
IRTC
$3.5B
| $12.4M | 0.24% |
105,026
-2,974
| -3% | -$429K |
2025 Q3
2 quarters
|
|
62
Adagio Medical Holdings
ADGM
$2.44M
| $11M | 0.22% |
9,876,576
| – | – |
2024 Q3
6 quarters
|
|
63
Evommune Inc
EVMN
$209M
| $10.3M | 0.2% |
+448,350
| New | +$10.1M |
2026 Q1
0 quarters
|
|
64
Phathom Pharmaceuticals
PHAT
$599M
| $10.3M | 0.2% |
+925,000
| New | +$11.7M |
2026 Q1
0 quarters
|
|
65
Neumora Therapeutics
NMRA
$66.6M
| $9.95M | 0.19% |
+5,104,097
| New | +$13.2M |
2026 Q1
0 quarters
|
|
66
Omada Health Inc
OMDA
$1.12B
| $9.88M | 0.19% |
786,330
-1,610,000
| -67% | -$22.2M |
2025 Q2
3 quarters
|
|
67
Neurocrine Biosciences
NBIX
$13.8B
| $8.57M | 0.17% |
65,050
-266,000
| -80% | -$35.3M |
2013 Q2
51 quarters
|
|
68
Beta Bionics
BBNX
$910M
| $8.45M | 0.17% |
842,944
+240,000
| +40% | +$3.55M |
2025 Q1
4 quarters
|
|
69
Opus Genetics
IRD
$341M
| $8.35M | 0.16% |
1,835,842
-2,489,158
| -58% | -$8.61M |
2025 Q1
4 quarters
|
|
70
BillionToOne Inc
BLLN
$4.62B
| $7.25M | 0.14% |
91,812
+19,000
| +26% | +$1.56M |
2025 Q4
1 quarter
|
|
71
Twist Bioscience
TWST
$9.82B
| $7.13M | 0.14% |
+150,000
| New | +$6.73M |
2026 Q1
0 quarters
|
|
72
Surrozen
SRZN
$279M
| $6.68M | 0.13% |
+229,393
| New | +$5.5M |
2026 Q1
0 quarters
|
|
73
AgomAb Therapeutics NV
AGMB
$428M
| $6.29M | 0.12% |
+600,000
| New | +$8.5M |
2026 Q1
0 quarters
|
|
74
Evolus
EOLS
$477M
| $5.29M | 0.1% |
+1,286,862
| New | +$6.24M |
2026 Q1
0 quarters
|
|
75
Cogent Biosciences
COGT
$4.88B
| $4.66M | 0.09% |
121,082
| – | – |
2025 Q4
1 quarter
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $685M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.
- Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
- Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
- Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
- Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
- Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
- Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
- Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.